€22.72
0.71% yesterday
Amsterdam, May 09, 05:37 pm CET
ISIN
BE0003818359
Symbol
GLPG
Sector
Industry

Galapagos Stock price

€22.72
+1.48 6.97% 1M
-3.52 13.41% 6M
-3.80 14.33% YTD
-4.10 15.29% 1Y
-32.36 58.75% 3Y
-186.58 89.14% 5Y
-15.28 40.21% 10Y
Amsterdam, Closing price Fri, May 09 2025
+0.16 0.71%
ISIN
BE0003818359
Symbol
GLPG
Sector
Industry

Key metrics

Market capitalization €1.50b
Enterprise Value €-1.79b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 8.07
EV/Sales (TTM) EV/Sales -6.21
P/S ratio (TTM) P/S ratio 5.20
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue €288.19m
EBIT (operating result TTM) EBIT €-351.89m
Free Cash Flow (TTM) Free Cash Flow €-221.66m
Cash position €3.30b
EPS (TTM) EPS €-2.57
P/E forward negative
P/S forward 5.39
EV/Sales forward negative
Show more

Is Galapagos a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,791 stocks worldwide.

Galapagos Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Galapagos forecast:

1x Buy
8%
8x Hold
67%
3x Sell
25%

Analyst Opinions

12 Analysts have issued a Galapagos forecast:

Buy
8%
Hold
67%
Sell
25%

Financial data from Galapagos

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
288 288
47% 47%
100%
- Direct Costs 46 46
17% 17%
16%
242 242
54% 54%
84%
- Selling and Administrative Expenses 147 147
45% 45%
51%
- Research and Development Expense 447 447
0% 0%
155%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -352 -352
68% 68%
-122%
Net Profit -170 -170
11% 11%
-59%

In millions EUR.

Don't miss a Thing! We will send you all news about Galapagos directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galapagos Stock News

Positive
Seeking Alpha
14 days ago
Galapagos NV released positive data from the phase 1/2 ATALANTA-1 study using GLPG5101 for the treatment of patients with relapsed/refractory Mantle Cell Lymphoma; 100% ORR/CR was achieved in 8 patients. Updated data from the relapsed/refractory Mantle Cell Lymphoma cohort from the phase 1/2 ATALANTA-1 study is to be presented at a medical conference presentation 2nd half of 2025. The global MC...
Neutral
Seeking Alpha
16 days ago
Galapagos NV (NASDAQ:GLPG ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Paul Stoffels - Chair, Chief Executive Officer Thad Huston - Chief Operating, Chief Financial Officer John Mellors - Head of Cell Therapy Discovery WulfBöcher - Head of Immunology Omotayo Fasan - Clinical Program Head, Oncology Valeria Cnossen - Executive and General Counsel Glenn Schulma...
Neutral
GlobeNewsWire
16 days ago
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Bo...
More Galapagos News

Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Head office Belgium
CEO Paulus Stoffels
Employees 704
Founded 1999
Website www.glpg.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today